CZ299182B6 - Vícedávková farmaceutická kompozice v tuhé perorální forme s rízeným uvolnováním, výhodne ve forme tablet nebo tvrdých želatinových kapslí s obsahem chloridu draselného - Google Patents
Vícedávková farmaceutická kompozice v tuhé perorální forme s rízeným uvolnováním, výhodne ve forme tablet nebo tvrdých želatinových kapslí s obsahem chloridu draselného Download PDFInfo
- Publication number
- CZ299182B6 CZ299182B6 CZ20002858A CZ20002858A CZ299182B6 CZ 299182 B6 CZ299182 B6 CZ 299182B6 CZ 20002858 A CZ20002858 A CZ 20002858A CZ 20002858 A CZ20002858 A CZ 20002858A CZ 299182 B6 CZ299182 B6 CZ 299182B6
- Authority
- CZ
- Czechia
- Prior art keywords
- potassium chloride
- pellets
- total weight
- composition
- coating
- Prior art date
Links
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 title claims abstract description 221
- 239000008188 pellet Substances 0.000 title claims abstract description 143
- 239000001103 potassium chloride Substances 0.000 title claims abstract description 110
- 235000011164 potassium chloride Nutrition 0.000 title claims abstract description 110
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000013270 controlled release Methods 0.000 title claims abstract description 9
- 239000007787 solid Substances 0.000 title claims abstract description 7
- 108010010803 Gelatin Proteins 0.000 title abstract 2
- 229920000159 gelatin Polymers 0.000 title abstract 2
- 239000008273 gelatin Substances 0.000 title abstract 2
- 235000019322 gelatine Nutrition 0.000 title abstract 2
- 235000011852 gelatine desserts Nutrition 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 115
- 239000002245 particle Substances 0.000 claims abstract description 94
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 34
- 239000000454 talc Substances 0.000 claims abstract description 18
- 229910052623 talc Inorganic materials 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 229920001577 copolymer Polymers 0.000 claims abstract description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 15
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000011247 coating layer Substances 0.000 claims abstract description 11
- 239000000975 dye Substances 0.000 claims abstract description 9
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims description 64
- 239000011248 coating agent Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 39
- 239000006185 dispersion Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000010410 layer Substances 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 238000005243 fluidization Methods 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 16
- 229920001296 polysiloxane Polymers 0.000 claims description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 13
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 13
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 239000007903 gelatin capsule Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000008119 colloidal silica Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- -1 polysiloxane Polymers 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 28
- 239000012153 distilled water Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 18
- 239000000839 emulsion Substances 0.000 description 17
- 239000013078 crystal Substances 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000002775 capsule Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 238000013268 sustained release Methods 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 238000010998 test method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 5
- 229960003988 indigo carmine Drugs 0.000 description 5
- 235000012738 indigotine Nutrition 0.000 description 5
- 239000004179 indigotine Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 229920004482 WACKER® Polymers 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000004815 dispersion polymer Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000012798 spherical particle Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000003912 environmental pollution Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000012178 vegetable wax Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000004569 hydrophobicizing agent Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9800369A HU221435B (en) | 1998-02-20 | 1998-02-20 | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ20002858A3 CZ20002858A3 (cs) | 2001-01-17 |
| CZ299182B6 true CZ299182B6 (cs) | 2008-05-14 |
Family
ID=89996172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20002858A CZ299182B6 (cs) | 1998-02-20 | 1999-02-19 | Vícedávková farmaceutická kompozice v tuhé perorální forme s rízeným uvolnováním, výhodne ve forme tablet nebo tvrdých želatinových kapslí s obsahem chloridu draselného |
Country Status (6)
| Country | Link |
|---|---|
| AU (1) | AU2540499A (sk) |
| CZ (1) | CZ299182B6 (sk) |
| HU (1) | HU221435B (sk) |
| PL (1) | PL193028B1 (sk) |
| SK (1) | SK287281B6 (sk) |
| WO (1) | WO1999042087A2 (sk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19928312A1 (de) * | 1999-06-16 | 2000-12-21 | Schering Ag | Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe |
| DE10347242A1 (de) * | 2003-10-10 | 2005-05-04 | Wella Ag | Farbstoffhaltige Pellets zum Färben von Keratinfasern |
| WO2007135470A1 (en) * | 2006-05-19 | 2007-11-29 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | Process for the preparation and surface coating of pellets |
| DE102008063800A1 (de) | 2008-12-19 | 2010-06-24 | Henkel Ag & Co. Kgaa | Beschichtete Färbemittel |
| CN102961363B (zh) * | 2012-12-14 | 2014-09-17 | 河南中帅医药科技股份有限公司 | 氯化钾缓释胶囊 |
| EP3213747B1 (en) | 2016-03-04 | 2019-02-13 | Laboratorio Reig Jofre S.A. | Tablets with a high-content of active ingredients useful for treating hair loss or stimulating its growth |
| EP4308286A1 (de) | 2021-03-16 | 2024-01-24 | Symrise AG | Wirkstoffkapseln |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2087235A (en) * | 1980-11-12 | 1982-05-26 | Ciba Geigy Ag | A granular delayed-release form of pharmaceutical active substances |
| GB2157170A (en) * | 1984-03-23 | 1985-10-23 | Ciba Geigy Ag | Quick-disintegrating pressed shapes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
| US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
-
1998
- 1998-02-20 HU HU9800369A patent/HU221435B/hu unknown
-
1999
- 1999-02-19 CZ CZ20002858A patent/CZ299182B6/cs not_active IP Right Cessation
- 1999-02-19 PL PL343268A patent/PL193028B1/pl unknown
- 1999-02-19 WO PCT/HU1999/000013 patent/WO1999042087A2/en active IP Right Grant
- 1999-02-19 SK SK1188-2000A patent/SK287281B6/sk not_active IP Right Cessation
- 1999-02-19 AU AU25404/99A patent/AU2540499A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2087235A (en) * | 1980-11-12 | 1982-05-26 | Ciba Geigy Ag | A granular delayed-release form of pharmaceutical active substances |
| GB2157170A (en) * | 1984-03-23 | 1985-10-23 | Ciba Geigy Ag | Quick-disintegrating pressed shapes |
Non-Patent Citations (1)
| Title |
|---|
| THOMA K ET AL "PREPARATION AND TESTING OF PATASSIUM CHLORIDE DIFFUSION PELLETS" PHARM IND (1989) 51 (6) 685-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9800369A1 (hu) | 2000-08-28 |
| WO1999042087A3 (en) | 1999-11-25 |
| HU9800369D0 (en) | 1998-04-28 |
| SK287281B6 (sk) | 2010-05-07 |
| WO1999042087A2 (en) | 1999-08-26 |
| SK11882000A3 (sk) | 2001-01-18 |
| CZ20002858A3 (cs) | 2001-01-17 |
| PL343268A1 (en) | 2001-08-13 |
| HU221435B (en) | 2002-10-28 |
| PL193028B1 (pl) | 2007-01-31 |
| AU2540499A (en) | 1999-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4666703A (en) | Storage-stable, quick-disintegrating pressed shapes containing pharmaceutical active substances | |
| US4728513A (en) | Granular delayed-release form of pharmaceutically active substances | |
| US6638535B2 (en) | Modified release formulations containing a hypnotic agent | |
| EP1187601B1 (en) | Novel preparation and administration form comprising an acid-labile proton pump inhibitor | |
| DE69123075T2 (de) | Ueberzogene Zusammensetzung sowie Verfahren zu ihrer Herstellung | |
| JP2538134B2 (ja) | 徐放性製剤およびその製造法 | |
| MXPA02002197A (es) | Formas de administracion farmaceuticas orales con accion retardada. | |
| WO1996019200A1 (fr) | Preparation granulaire a liberation prolongee et procede de production | |
| CZ20004362A3 (en) | Pharmaceutical preparation provided with enterosolvent coating and process of its preparation | |
| GB2087235A (en) | A granular delayed-release form of pharmaceutical active substances | |
| KR20000076475A (ko) | 약제학적 활성 성분의 함량이 90중량% 이하인 펠렛의제조방법 | |
| MXPA06003602A (es) | Formulaciones de microparticulas de pantoprazol. | |
| CN101094675A (zh) | [1,4]二氮杂庚因并[6,7,1－ij]喹啉衍生物制剂 | |
| JP3987282B2 (ja) | 粒状化結晶性イブプロフェンで被覆した粒子 | |
| EP2153834A2 (en) | Extended release pharmaceutical compositions comprising quetiapine salts | |
| CZ2006269A3 (cs) | Pelety obsahující hydrochlorid venlafaxinu | |
| CZ299182B6 (cs) | Vícedávková farmaceutická kompozice v tuhé perorální forme s rízeným uvolnováním, výhodne ve forme tablet nebo tvrdých želatinových kapslí s obsahem chloridu draselného | |
| CZ83299A3 (cs) | Dávková forma [R-(Z)]-alfa-(methoxyimino)-alfa-(1-azabicyklo[2,2,2]okt-3-yl)acetonitril monohydrochloridu s řízeným uvolňováním | |
| US20080113030A1 (en) | Sustained release tamsulosin formulations | |
| JPH04338323A (ja) | 放出制御製剤およびその製造法 | |
| CZ382696A3 (en) | Medicinal form containing carbamazepine with delayed release of active component | |
| JPS62181214A (ja) | 徐放性粒状物の製造法 | |
| RU2092155C1 (ru) | Способ получения твердого лекарственного препарата для перорального введения | |
| HU191102B (en) | Process for producing pharmaceutical compositions of regulated dissolution of the active agents containing water-soluble inorganic pharmacons | |
| CZ2007658A3 (cs) | Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Effective date: 20190219 |